High-risk clinicopathological features, such as tumor size >2 cm, extrathyroidal extension, and aggressive histological variants, are discussed alongside molecular markers (BRAF V600E, TERT, RET/PTC) that predict metastatic potential. This evidence concerns the gene BRAF and neoplasm.